What is it about?

Sirolimus is among many immunomodulator drugs used in medicine. It has potential applications in eye diseases specifically, uveitis. This paper examines all the available data regarding this drug to come up with a general conclusion in terms of its safety and efficacy. To date, sirolimus appears to be beneficial in treating patients with non-infectious uveitis.

Featured Image

Why is it important?

While uveitis may be an unheard eye condition to the layperson, according to some studies, it actually is the 3rd leading cause of preventable blindness in the world. Treatment with corticosteroids is readily available however limitations to its use stem from complications due to prolonged use. Thus, alternative therapy includes a variety of immunomodulator drugs. The most optimal choice of which is one that is both effective and tolerable. Current evidence suggests that sirolimus may be a potential candidate favored by the recent clinical trials we have analyzed.


A lot of research is centered on drug development and the process entails a tedious one involving drug companies as well as the Food and Drug Administration (FDA). When novel therapy comes to light and shows promise, it is our hope that these may acquire FDA approval and that it may be made available to the general public who may benefit from its use. Nevertheless, extensive trials and research must first be undertaken to ensure patient safety and well-being. The main purpose of this review article was to explore off-label treatments for non-infectious uveitis, in this case, sirolimus. We hope to contribute unbiased evidence regarding its potential use for this eye disease.

Vicente Lorenzo Cabahug
St. Luke's Medical Center - Eye Institute

Read the Original

This page is a summary of: Outcomes of treatment with sirolimus for non-infectious uveitis: a meta-analysis and systematic review, Clinical Ophthalmology, April 2019, Dove Medical Press, DOI: 10.2147/opth.s198401.
You can read the full text:

Open access logo



The following have contributed to this page